—

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-10-08 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 11 of 12 in its cohort on the Closelooknet composite (48/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 48 35 53 63 warn 18.6%
LLY Eli Lilly and Company 64 69 92 29 bull 8%
ORNAV.HE Orion Oyj A 62 79 84 34 ok 4.6%
ORNBV.HE Orion Oyj B 62 80 84 34 ok 4.4%
AMGN Amgen Inc 55 77 85 42 bull 7.6%
NVO Novo Nordisk A/S 55 25 87 75 bear 38.2%
GSK GlaxoSmithKline PLC ADR 52 26 80 58 info 22.6%
EL.PA EssilorLuxottica S. A. 45 8 48 59 bear 53.6%
HALO Halozyme Therapeutics Inc 74 94 94 51 ok 6%
BION.SW BB Biotech AG 73 57 96 81 info 16.1%
DXCM DexCom Inc 66 83 80 37 watch 9%
ANN.AU Ansell Ltd 64 94 47 53 ok 1.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-08

Quick answers

Who are Virbac SA's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Amgen Inc (AMGN), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC ADR (GSK), EssilorLuxottica S. A. (EL.PA), Halozyme Therapeutics Inc (HALO) and others.

How does VIRP.PA score against its peers?

Virbac SA's composite reads 48/100, ranking 11 of 12 in its cohort as of 2026-10-08; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.